Getting high to cope with COVID-19: Modelling the associations between cannabis demand, coping motives, and cannabis use and problems.

Adaptation, Psychological COVID-19 Cannabis Humans Motivation Pandemics SARS-CoV-2
Behavioral economics Cannabis Demand Motives

Journal

Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486

Informations de publication

Date de publication:
01 2022
Historique:
received: 27 04 2021
revised: 06 08 2021
accepted: 19 08 2021
pubmed: 2 9 2021
medline: 16 10 2021
entrez: 1 9 2021
Statut: ppublish

Résumé

During the COVID-19 pandemic, people may use substances like cannabis for enhancement or coping purposes. Behavioral economic demand for a substance is a key determinant of its use and misuse and can be measured via hypothetical purchase tasks. Previous research suggests that motivations to use a substance play a mediational role between elevated substance demand and problems, but comparable mechanistic research has yet to be done in the COVID-19 context and on the effects of cannabis demand on cannabis use patterns. Participants (n = 137) were recruited via the online crowdsourcing platform Prolific. Participants completed measures of cannabis use and problems, motivations for cannabis use, and the Marijuana Purchase Task. Two indices of demand, Persistence (i.e., sensitivity to increasing cost of cannabis) and Amplitude (i.e., consumption of cannabis at unrestricted cost), were related to increased cannabis problems via the use motive of coping during the COVID-19 pandemic. This model did not support the mediational role of enhancement motives. Those with increased cannabis demand who tend to use cannabis to cope are at increased risk of experiencing negative cannabis-related consequences during the COVID-19 pandemic.

Identifiants

DOI: 10.1016/j.addbeh.2021.107092 PMID: 34469783 PMC: PMC8555961
pubmed: 34469783
pii: S0306-4603(21)00277-X
doi: 10.1016/j.addbeh.2021.107092
pmc: PMC8555961
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107092

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

J Addict Med. 2020 Dec 14;:
pubmed: 33323693
J Consult Clin Psychol. 2000 Oct;68(5):898-908
pubmed: 11068976
Addict Behav. 2012 Nov;37(11):1257-63
pubmed: 22727784
Annu Rev Clin Psychol. 2014;10:641-77
pubmed: 24679180
Exp Clin Psychopharmacol. 2015 Oct;23(5):377-86
pubmed: 26147181
Exp Clin Psychopharmacol. 2021 Feb;29(1):23-35
pubmed: 32105138
Psychol Trauma. 2020 May;12(4):331-335
pubmed: 32271070
Exp Clin Psychopharmacol. 2008 Feb;16(1):57-65
pubmed: 18266552
Alcohol Clin Exp Res. 2020 Oct;44(10):2073-2083
pubmed: 32870516
Behav Processes. 2015 Apr;113:187-91
pubmed: 25712039
PLoS One. 2017 May 26;12(5):e0178194
pubmed: 28552942
Biol Psychiatry. 2016 Aug 1;80(3):179-89
pubmed: 26772405
Psychol Addict Behav. 2016 Dec;30(8):819-826
pubmed: 28068111
Addict Behav. 2007 Dec;32(12):3122-30
pubmed: 17602842
Psychiatry Res. 2020 Nov;293:113407
pubmed: 32827993
Exp Clin Psychopharmacol. 2019 Apr;27(2):109-114
pubmed: 30475012
Psychopharmacology (Berl). 2017 Aug;234(16):2421-2429
pubmed: 28508921
Psychol Rev. 2008 Jan;115(1):186-98
pubmed: 18211190
Drug Alcohol Depend. 2017 Sep 1;178:136-142
pubmed: 28647681
Psychol Sci. 2007 Mar;18(3):233-9
pubmed: 17444920
Exp Clin Psychopharmacol. 2015 Jun;23(3):168-75
pubmed: 25895013
Addiction. 2016 Nov;111(11):1956-1965
pubmed: 27318078
J Subst Abuse Treat. 2009 Jun;36(4):400-13
pubmed: 19004601
J Stud Alcohol Drugs. 2011 Nov;72(6):991-9
pubmed: 22051213
Exp Clin Psychopharmacol. 2006 May;14(2):219-27
pubmed: 16756426
Psychopharmacology (Berl). 2014 Mar;231(5):889-97
pubmed: 24217899
Exp Clin Psychopharmacol. 1999 Nov;7(4):412-26
pubmed: 10609976
Drug Alcohol Depend. 2015 Jul 1;152:32-8
pubmed: 26002377
Addict Behav. 2018 Jan;76:139-144
pubmed: 28820970
Alcohol Clin Exp Res. 2012 Apr;36(4):716-24
pubmed: 22017303
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Nicotine Tob Res. 2012 Dec;14(12):1426-34
pubmed: 22416117
Psychopharmacology (Berl). 2009 Mar;203(1):33-40
pubmed: 18925387
J Stud Alcohol Drugs. 2018 Nov;79(6):929-934
pubmed: 30573024
Behav Processes. 2017 Jul;140:33-40
pubmed: 28347716
Exp Clin Psychopharmacol. 2014 Jun;22(3):211-21
pubmed: 24467370
Addict Behav. 2007 Jul;32(7):1384-94
pubmed: 17097817
Exp Clin Psychopharmacol. 2019 Aug 05;:
pubmed: 31380693
Curr Opin Psychol. 2019 Dec;30:42-47
pubmed: 30807957
Drug Alcohol Depend. 2010 Jul 1;110(1-2):137-43
pubmed: 20347232
Addiction. 2020 May;115(5):817-831
pubmed: 31656048

Auteurs

L Vedelago (L)

Department of Psychology, York University, Toronto, ON, Canada. Electronic address: lvedelag@yorku.ca.

J D Wardell (JD)

Department of Psychology, York University, Toronto, ON, Canada; Institute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

T Kempe (T)

Department of Psychology, University of Manitoba, Winnipeg, MB, Canada.

H Patel (H)

Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, ON, Canada.

M Amlung (M)

Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, ON, Canada; Department of Applied Behavioral Science, University of Kansas, Lawrence, KS, United States.

J MacKillop (J)

Department of Psychiatry and Behavioural Neuroscience, McMaster University, Hamilton, ON, Canada; Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada; Homewood Research Institute, Guelph, ON, Canada.

M T Keough (MT)

Department of Psychology, York University, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Comportement et mécanismes comportementaux › Adaptation psychologique › Getting high to cope with COVID-19: Modelling...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Getting high to cope with COVID-19: Modelling...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Rosanae › Rosales › Cannabaceae › Cannabis › Getting high to cope with COVID-19: Modelling...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Getting high to cope with COVID-19: Modelling...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Personnalité › Intelligence › Intelligence émotionnelle › Motivation › Getting high to cope with COVID-19: Modelling...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Getting high to cope with COVID-19: Modelling...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Getting high to cope with COVID-19: Modelling...